Loading
A phase 2 trial of sacituzumab tirumotecan in lung cancer, run by Zhejiang Cancer Hospital, not yet recruiting.
Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases is a phase 2, interventional study registered as NCT07343479 by Zhejiang Cancer Hospital, with a registry enrolment figure of 45 participants, started 2026-05-01 and due to reach its primary completion in 2027-06-20. Interventions recorded: sac-TMT plus EGFR-TKI. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); EGFR Gene Mutations; Brain Metastasis. Primary outcome: 6-month PFS rate. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed non-squamous NSCLC, and metastatic (Stage IV);". Sites: China. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Lung cancer trials open today (registry snapshot), Antibody-drug conjugate (ADC) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.